Commissioning antibody protein sequencing: how de novo antibody sequencing or an antibody sequencing service recovers a variable region when hybridoma sequencing is no longer possible, what a hybridoma antibody leaves you with, what protein sequencing services deliver, and the antibody expression test that proves the sequence

The two routes and what each needs

1. From the cell, which is far easier, while you still have it. If the hybridoma or the producing cell line is alive, the variable region sequences are recovered from its messenger RNA by amplification and sequencing. It is cheap, fast and unambiguous. Do it while the line is healthy rather than after it is not.
2. From purified protein, when the cell is gone. De novo sequencing by mass spectrometry reconstructs the sequence from overlapping peptides. It needs a few hundred micrograms of purified antibody, several proteases to produce overlapping coverage, and it is a considerably larger analytical exercise.
3. Insist on full coverage of the complementarity determining regions. The binding regions are where errors matter and where coverage is hardest, because they are the most variable. A report with gaps in those loops has not delivered a usable sequence, whatever the overall coverage percentage says.
4. Watch the isobaric residues. Leucine and isoleucine have identical mass and cannot be distinguished by ordinary mass spectrometry, and there are similar traps. A good provider states how it resolved them, or states that it did not, and an unresolved position has to be tested by expression.
5. Prove the sequence by expressing it. The only real validation is to express the recombinant antibody from the reported sequence and show it binds like the original, in the assay you care about. A sequence that has not been expressed is a hypothesis, and the expression test should be part of the project.

What to agree before sending material

Who owns the resulting sequence, whether the provider may retain or reuse it, what the deliverable format is, and whether expression validation is included or extra. Ownership of a sequence derived from your reagent is a term worth reading closely.

Agree the acceptance criteria: coverage across the variable regions, how ambiguous positions are reported, and what happens if coverage falls short. A report with gaps and no remedy clause is a poor outcome nobody planned for.

Preparing the sample

Send purified, carrier-free antibody in a simple buffer. Bovine serum albumin, gelatin and other stabilisers in a formulated reagent all interfere, and ascites or serum-derived material brings the host's own immunoglobulin with it.

Send more than the minimum. A repeat digest with another protease is often what closes a coverage gap, and it is much faster if the material is already there.

After the sequence arrives

Express it, purify it, and compare against the original in the assay you actually use, not only in a binding measurement. Then bank the plasmid and the sequence somewhere that is not one laptop.

Record the sequence with the reagent's history: which clone, which lot it was derived from and who sequenced it. That record is what makes the reagent citable in a methods section a decade later.

Common questions

Can an antibody be sequenced from purified protein alone?

Yes, by de novo mass spectrometry using several proteases to generate overlapping peptides. It needs a few hundred micrograms of pure antibody and it is harder and more expensive than sequencing from the cell that makes it.

How much antibody do protein sequencing services need?

Typically a few hundred micrograms of purified, homogeneous material. Contaminating immunoglobulin from serum or a carrier protein in the formulation complicates the analysis considerably, so supply carrier-free purified material.

How accurate is de novo antibody sequencing?

Good providers achieve high coverage, and the difficult part is the binding loops and residues with identical mass. Expressing the sequence and showing the recombinant binds like the original is the only proof that settles it.

Why sequence an antibody at all?

To make it permanent. A sequence can be expressed indefinitely, reformatted into any isotype or fragment, produced anywhere and shared, while a hybridoma drifts, can be lost and exists in one freezer.

Browse by service class

• Compare Gene synthesis on advertised prices